Saccharomyces boulardii

(redirected from S. boulardii)

saccharomyces boulardii

(sak-a-roe-mye-seez boo-lar-dee) ,

Brewer's yeast

(trade name),


(trade name)


Therapeutic: antidiarrheals
Treatment and prevention of diarrhea Irritable bowel syndrome.


Saccharomyces boulardii is a non-pathogenic yeast used to colonize the gastrointestinal tract.

Therapeutic effects

Reduced number of bowel movements.


Absorption: Unknown
Distribution: Unknown
Metabolism and Excretion: Unknown
Half-life: Unknown

Time/action profile

POunknown3 daysunknown


Contraindicated in: Hypersensitivity to yeast.
Use Cautiously in: Pregnancy and lactation;Immunocompromised patients (↑ risk of fungemia)

Adverse Reactions/Side Effects


  • bloating
  • constipation
  • flatulence


  • fungemia
  • ↑ thirst


Antifungals may decrease effectiveness of Saccharomyces boulardii None.
Oral (Adults) 250–500 mg two to four times a day


Capsules: 250 mg

Nursing implications

Nursing assessment

  • Assess patient for abdominal distention, presence of bowel sounds, and usual pattern of bowel function.
  • Assess color, consistency, and amount of stool produced.
  • Lab Test Considerations: Monitor CBC periodically during therapy.

Potential Nursing Diagnoses

Diarrhea (Indications)


  • Oral: Administer as directed.

Patient/Family Teaching

  • Instruct patient to take as directed.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Resolution of diarrhea and decrease in number of loose stools.

Saccharomyces boulardii

a yeast species widely prescribed for treatment of diarrhea. Molecular typing shows it to be nearly identical, genetically, to S. cerevisiae; however it is metabolically and physiologically different.
See also: Saccharomyces.

Saccharomyces boulardii

A species of yeast that is used as a probiotic to prevent and treat infectious and inflammatory diseases of the intestines.
See also: Saccharomyces
References in periodicals archive ?
She was scientific director for the company that manufactures the S.
The evidence: In a meta-analysis of 15 studies, adults on antibiotics were 52 percent less likely to have diarrhea if they took S.
Intestinal cell barrier functions disrupted by Clostridia are preserved by S.
The finding--which nevertheless does "not allow the exclusion of the potential therapeutic efficacy of probiotics"--comes from the third study to assess S.
They were then randomized to receive either oral S.
boulardii, they found that the simple act of opening a packet of S.
Hospitalized patients for whom clinicians may consider use of a probiotic to manage severe and/or recurrent CDI often have many of the above risk factors for development of fungemia, making administration of S.
Eric Line, who is in the ARS Poultry Microbiological Safety Research Unit at Athens, Georgia, found that feeding chickens the S.
Evidence: "There are well-done, big, blinded studies that show that S.
Growing evidence suggests that probiotics such as the live, nonpathogenic yeast S.
difficile infection were treated with vancomycin or metronidazole and were randomly assigned to receive, in double-blind fashion, S.